Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2011

01.07.2011 | Hepatobiliary Tumors

Risk Factors, Prognosis, and Management of Early and Late Intrahepatic Recurrence After Resection of Primary Clear Cell Carcinoma of the Liver

verfasst von: Tao Li, MD, Jia Fan, MD, Lun-Xiu Qin, MD, Jian Zhou, MD, Hui-Chuan Sun, MD, Shuang-Jian Qiu, MD, Qing-Hai Ye, MD, Lu Wang, MD, Zhao-You Tang, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary clear cell carcinoma of the liver (PCCCL) is an uncommon variant of hepatocellular carcinoma (HCC). The prognostic factors influencing its recurrence and survival are not clarified. This study is to evaluate the predictive factors, the therapy, and prognosis of intrahepatic recurrences after resection of PCCCL.

Methods

A total of 214 PCCCL patients treated by curative resection from January 1996 to March 2006 were retrospectively analyzed. Intrahepatic recurrences were classified into early (≤1 year) and late (>1 year) recurrences.

Results

The 1-, 3-, and 5-year overall survival (OS) rates for PCCCL patients were significantly better than those of HCC patients (P = .001). Serum a-fetoprotein (AFP) level, tumor size, liver cirrhosis, and vascular invasion were independent risk factors for both OS and disease-free survival (DFS) of PCCCL. Early and late intrahepatic recurrences developed in 28 patients and 71 patients, respectively. In multivariate analysis, ALT level and vascular invasion were independent risk factors for early recurrence, whereas age was the only significant risk factor for late recurrence. OS of late-recurrence group was significantly better than that of early-recurrence group (P = .001), and re-resection rate was higher in late than in early-recurrence group (P = .04). The 1-, 3-, and 5-year OS of patients with recurrence who received curative treatment was comparable to those who never had tumor recur (P = .71).

Conclusion

PCCCL has a better prognosis and tends to recur later than HCC. Early and late recurrences of PCCCL are linked to different predictive factors. The time to recurrence and feasibility of curative treatment are the best determinants for the prognosis.
Literatur
1.
Zurück zum Zitat Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4:252–61.PubMedCrossRef Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4:252–61.PubMedCrossRef
2.
Zurück zum Zitat Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med. 1999;123:524–8.PubMed Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med. 1999;123:524–8.PubMed
3.
Zurück zum Zitat Ross JS, Kurian S. Clear cell hepatocellular carcinoma: sudden death from severe hypoglycemia. Am J Gastroenterol. 1985;80:188–94.PubMed Ross JS, Kurian S. Clear cell hepatocellular carcinoma: sudden death from severe hypoglycemia. Am J Gastroenterol. 1985;80:188–94.PubMed
4.
Zurück zum Zitat Liu Z, Ma W, Li H, Li Q. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res. 2008;38:291–9.PubMedCrossRef Liu Z, Ma W, Li H, Li Q. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res. 2008;38:291–9.PubMedCrossRef
5.
Zurück zum Zitat Emile JF, Lemoine A, Azoulay D, Debuire B, Bismuth H, Reynès M. Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. Histopathology. 2001;38:225–31.PubMedCrossRef Emile JF, Lemoine A, Azoulay D, Debuire B, Bismuth H, Reynès M. Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. Histopathology. 2001;38:225–31.PubMedCrossRef
6.
Zurück zum Zitat Yang SH, Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on clear cell hepatocellular carcinoma. Pathol Int. 1996;46:503–9.PubMedCrossRef Yang SH, Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on clear cell hepatocellular carcinoma. Pathol Int. 1996;46:503–9.PubMedCrossRef
7.
Zurück zum Zitat Wu PC, Lai CL, Lam KC, Lok AS, Lin HJ. Clear cell carcinoma of liver. An ultrastructural study. Cancer. 1983;52:504–7.PubMedCrossRef Wu PC, Lai CL, Lam KC, Lok AS, Lin HJ. Clear cell carcinoma of liver. An ultrastructural study. Cancer. 1983;52:504–7.PubMedCrossRef
8.
Zurück zum Zitat Buchanan TF Jr, Huvos AG. Clear-cell carcinoma of the liver. A clinicopathologic study of 13 patients. Am J Clin Pathol. 1974;61:529–39.PubMed Buchanan TF Jr, Huvos AG. Clear-cell carcinoma of the liver. A clinicopathologic study of 13 patients. Am J Clin Pathol. 1974;61:529–39.PubMed
9.
Zurück zum Zitat Orsatti G, Arnold MM, Paronetto F. DNA image cytometric analysis of primary clear cell carcinoma of the liver. Arch Pathol Lab Med. 1994;118:1226–9.PubMed Orsatti G, Arnold MM, Paronetto F. DNA image cytometric analysis of primary clear cell carcinoma of the liver. Arch Pathol Lab Med. 1994;118:1226–9.PubMed
10.
Zurück zum Zitat Lai CL, Wu PC, Lam KC, Todd D. Histologic prognostic indicators in hepatocellular carcinoma. Cancer. 1979;44:1677–83.PubMedCrossRef Lai CL, Wu PC, Lam KC, Todd D. Histologic prognostic indicators in hepatocellular carcinoma. Cancer. 1979;44:1677–83.PubMedCrossRef
11.
Zurück zum Zitat McDermott WV, Cady B, Georgi B, Steele G Jr, Khettry U. Primary cancer of the liver. Evaluation, treatment, and prognosis. Arch Surg. 1989;124:552–4.PubMed McDermott WV, Cady B, Georgi B, Steele G Jr, Khettry U. Primary cancer of the liver. Evaluation, treatment, and prognosis. Arch Surg. 1989;124:552–4.PubMed
12.
Zurück zum Zitat Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol. 2000;33:282–9.PubMedCrossRef Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol. 2000;33:282–9.PubMedCrossRef
13.
Zurück zum Zitat Edmondson HA. Tumours of the liver and intrahepatic bile ducts. In: Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology, 1958;49. Edmondson HA. Tumours of the liver and intrahepatic bile ducts. In: Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology, 1958;49.
14.
Zurück zum Zitat Choi D, Lim HK, Rhim H, Kim YS, Yoo BC, Paik SW, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol. 2007;14:2319–29.PubMedCrossRef Choi D, Lim HK, Rhim H, Kim YS, Yoo BC, Paik SW, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol. 2007;14:2319–29.PubMedCrossRef
15.
Zurück zum Zitat Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.PubMedCrossRef Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.PubMedCrossRef
16.
Zurück zum Zitat Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216–22.PubMedCrossRef Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216–22.PubMedCrossRef
17.
Zurück zum Zitat Yang W, Chen MH, Yin SS, Yan K, Gao W, Wang YB, et al. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence. Am J Roentgenol. 2006;186:S275–83.CrossRef Yang W, Chen MH, Yin SS, Yan K, Gao W, Wang YB, et al. Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence. Am J Roentgenol. 2006;186:S275–83.CrossRef
18.
Zurück zum Zitat Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, et al. Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol. 2009;18:25–30.PubMedCrossRef Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, et al. Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol. 2009;18:25–30.PubMedCrossRef
19.
Zurück zum Zitat Jwo SC, Chiu JH, Chau GY, Loong CC, Lui WY. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology. 1992;16:1367–71.PubMedCrossRef Jwo SC, Chiu JH, Chau GY, Loong CC, Lui WY. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology. 1992;16:1367–71.PubMedCrossRef
20.
Zurück zum Zitat Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels. HPB Surg. 1996;10:97–103.PubMedCrossRef Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels. HPB Surg. 1996;10:97–103.PubMedCrossRef
21.
Zurück zum Zitat Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457–60.PubMedCrossRef Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457–60.PubMedCrossRef
22.
Zurück zum Zitat Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990;211:28–33.PubMedCrossRef Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990;211:28–33.PubMedCrossRef
23.
Zurück zum Zitat Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996;83:1219–22.PubMedCrossRef Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996;83:1219–22.PubMedCrossRef
24.
Zurück zum Zitat Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.PubMedCrossRef Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.PubMedCrossRef
25.
Zurück zum Zitat Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.PubMedCrossRef Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.PubMedCrossRef
26.
Zurück zum Zitat Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 1995;108:768–75.PubMedCrossRef Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 1995;108:768–75.PubMedCrossRef
27.
Zurück zum Zitat Tarao K, Rino Y, Takemiya S, Tamai S, Miyakawa K, Takakura H, et al. Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma. Intervirology. 2000;43:20–6.PubMedCrossRef Tarao K, Rino Y, Takemiya S, Tamai S, Miyakawa K, Takakura H, et al. Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma. Intervirology. 2000;43:20–6.PubMedCrossRef
28.
Zurück zum Zitat Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997;79:688–94.PubMedCrossRef Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997;79:688–94.PubMedCrossRef
29.
Zurück zum Zitat Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int. 2005;25:85–90.PubMedCrossRef Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int. 2005;25:85–90.PubMedCrossRef
30.
Zurück zum Zitat Tarao K, Hoshino H, Shimizu A, Ohkawa S, Nakamura Y, Harada M, et al. Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn J Cancer Res. 1994;85:1040–4.PubMed Tarao K, Hoshino H, Shimizu A, Ohkawa S, Nakamura Y, Harada M, et al. Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn J Cancer Res. 1994;85:1040–4.PubMed
31.
Zurück zum Zitat Taketomi A, Takenaka K, Matsumata T, Shimada M, Higashi H, Shirabe K, et al. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection. Hepatogastroenterology. 1997;44:477–83.PubMed Taketomi A, Takenaka K, Matsumata T, Shimada M, Higashi H, Shirabe K, et al. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection. Hepatogastroenterology. 1997;44:477–83.PubMed
32.
Zurück zum Zitat Arase Y, Chayama K, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C. Hepatol Res. 2001;21:55–66.PubMedCrossRef Arase Y, Chayama K, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C. Hepatol Res. 2001;21:55–66.PubMedCrossRef
33.
Zurück zum Zitat Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458–65.PubMedCrossRef Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458–65.PubMedCrossRef
34.
Zurück zum Zitat Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001;134:963–7.PubMed Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001;134:963–7.PubMed
35.
Zurück zum Zitat Lyman GH, Lyman S, Balducci L, Kuderer N, Reintgen D, Cox C, et al. Age and the risk of breast cancer recurrence. Cancer Control. 1996;3:421–7.PubMed Lyman GH, Lyman S, Balducci L, Kuderer N, Reintgen D, Cox C, et al. Age and the risk of breast cancer recurrence. Cancer Control. 1996;3:421–7.PubMed
36.
Zurück zum Zitat Yamazaki H, Inoue T, Koizumi M, Yoshida K, Kagawa K, Shiomi H, et al. Age as a prognostic factor for late local recurrence of early tongue cancer treated with brachytherapy. Anticancer Res. 1997;17:4709–12.PubMed Yamazaki H, Inoue T, Koizumi M, Yoshida K, Kagawa K, Shiomi H, et al. Age as a prognostic factor for late local recurrence of early tongue cancer treated with brachytherapy. Anticancer Res. 1997;17:4709–12.PubMed
37.
Zurück zum Zitat Shimada K, Sakamoto Y, Esaki M, Kosuge T, Morizane C, Ikeda M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2007;14:2337–47.PubMedCrossRef Shimada K, Sakamoto Y, Esaki M, Kosuge T, Morizane C, Ikeda M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2007;14:2337–47.PubMedCrossRef
38.
Zurück zum Zitat Chan KM, Lee WC, Hung CF, Yu MC, Jan YY, Chen MF. Aggressive multimodality treatment for intra-hepatic recurrence of hepatocellular carcinoma following hepatic resection. Chang Gung Med J. 2005;28:543–50.PubMed Chan KM, Lee WC, Hung CF, Yu MC, Jan YY, Chen MF. Aggressive multimodality treatment for intra-hepatic recurrence of hepatocellular carcinoma following hepatic resection. Chang Gung Med J. 2005;28:543–50.PubMed
39.
Zurück zum Zitat Tanaka K, Shimada H, Togo S, Takahashi T, Endo I, Sekido H, et al. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology. 1999;46:1083–8.PubMed Tanaka K, Shimada H, Togo S, Takahashi T, Endo I, Sekido H, et al. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology. 1999;46:1083–8.PubMed
40.
Zurück zum Zitat Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996,334:1561–7.PubMedCrossRef Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996,334:1561–7.PubMedCrossRef
41.
Zurück zum Zitat Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999;340:1046–7.PubMedCrossRef Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999;340:1046–7.PubMedCrossRef
42.
Zurück zum Zitat Biselli M, Andreone P, Gramenzi A, Trevisani F, Cursaro C, Rossi C, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol. 2005;3:918–25.PubMedCrossRef Biselli M, Andreone P, Gramenzi A, Trevisani F, Cursaro C, Rossi C, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol. 2005;3:918–25.PubMedCrossRef
43.
Zurück zum Zitat Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.PubMedCrossRef Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.PubMedCrossRef
44.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef
Metadaten
Titel
Risk Factors, Prognosis, and Management of Early and Late Intrahepatic Recurrence After Resection of Primary Clear Cell Carcinoma of the Liver
verfasst von
Tao Li, MD
Jia Fan, MD
Lun-Xiu Qin, MD
Jian Zhou, MD
Hui-Chuan Sun, MD
Shuang-Jian Qiu, MD
Qing-Hai Ye, MD
Lu Wang, MD
Zhao-You Tang, MD
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1540-z

Weitere Artikel der Ausgabe 7/2011

Annals of Surgical Oncology 7/2011 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.